DexCom, Inc. DXCM recently collaborated with Companion Medical to enable a direct exchange of CGM (Continuous Glucose Monitoring) data from InPen into both the companies’ software applications. The ...
Dexcom is a buy despite a recent slowdown in US sales. The upcoming launch of Stelo, a glucose monitor for non-insulin users, has a large potential market and is expected. Ex-US growth remains strong ...
Mike Kratky, an analyst from Leerink Partners, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target was lowered to $87.00. Mike Kratky’s rating is based on ...
Matthew Taylor, an analyst from Jefferies, reiterated the Buy rating on Dexcom (DXCM – Research Report). The associated price target remains the same with $100.00. Discover outperforming stocks and ...
The Dexcom G4 receiver, which will have an "identical" form factor to the forthcoming Bluetooth version. In a call to investors days after its app won FDA approval, Dexcom CEO Kevin Sayer shared some ...
Zacks Investment Research on MSN
Here's why you should hold DexCom stock in your portfolio for now
DexCom, Inc. DXCM is well-poised for growth in the coming quarters, backed by a huge potential in the continuous glucose monitoring (CGM) market. A strong third-quarter 2025 performance and a series ...
DexCom, Inc. DXCM recently collaborated with Companion Medical to enable a direct exchange of CGM (Continuous Glucose Monitoring) data from InPen into both the companies’ software applications. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback